Gene-guided medicine dosing for children with leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether using a child's genetic test results to adjust the dose of a common leukemia medicine (6-MP) during maintenance therapy can reduce side effects and improve safety. Children with ALL (a type of blood cancer) who are starting maintenance treatment may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have acute lymphoblastic leukemia (ALL) and be about to start maintenance therapy (the phase of treatment that helps keep cancer from coming back).
- Your child must be scheduled to take the oral medicine 6-mercaptopurine (also called 6-MP).
- Your child's genetic test results for NUDT15 and TPMT genes must be available (these tests check how the body processes 6-MP).
- Your child's liver and kidney function must be within acceptable limits (based on blood tests).
- Your child must not have Down syndrome, relapsed or treatment-resistant disease, or a history of stem cell transplant.
- Your child must not have severe organ failure or an uncontrolled infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at the diagnosis, treatment, and survival of children with a specific type of leukemia called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It aims to understand how well standard treatments, including targeted therapy, work in these patients.
This trial is for children newly diagnosed with acute lymphoblastic leukemia (ALL). It tests whether checking medicine levels in the blood can help optimize ongoing treatment (maintenance) and potentially keep the cancer under control.
This trial tests a new treatment approach for children and teens with high-risk acute lymphoblastic leukemia (ALL). It aims to improve outcomes for those with certain genetic changes or cancer that has spread.
This study looks at whether some children and young adults with B-ALL can safely get a transplant without total body irradiation (TBI), based on special leukemia test results. It’s meant to help lower radiation-related risks while keeping leukemia control strong.
This study tests a support program that helps parents give their child's daily leukemia medicine (6-MP) on schedule and overcome any barriers. It aims to make it easier for families to stick with treatment.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
Hear when a new Childhood Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.